Based on current spot rates, foreign exchange is now expected to be a headwind to reported Net sales growth of approximately one to two percentage points vs one percentage point previously expected. Reflecting a softer than anticipated start to the cough, cold and flu season and increased impact of foreign exchange, Kenvue tightened its net sales outlook expecting fiscal 2023 reported Net sales growth to be in the range of 4.0% to 4.5% and Organic growth to be in the range of 5.5% to 6.0%. FY23 revenue consensus $15.67B.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on KVUE:
- CVS Health (NYSE:CVS) Empties Certain Decongestants from Store Shelves
- CVS removing certain cold medicines containing phenylephrine, CNBC reports
- Kenvue price target lowered to $23 from $27 at HSBC
- Kenvue price target lowered to $27 from $30 at BofA
- RBC Analyst Bullish on Johnson & Johnson (NYSE: JNJ) Post-Spinoff